Related Experiment Video

Updated: May 1, 2026

A Surgical Model of Heart Failure with Preserved Ejection Fraction in Tibetan Minipigs
07:09

A Surgical Model of Heart Failure with Preserved Ejection Fraction in Tibetan Minipigs

Published on: February 18, 2022

2.2K

TOPCAT misses its primary endpoint: Should spironolactone be abandoned in HFpEF?

Ahmed M Elguindy1

  • 1Aswan Heart Centre, Aswan, Egypt.

Global Cardiology Science & Practice
|April 22, 2014
PubMed

Insights

Spironolactone, an aldosterone antagonist, was tested in the TOPCAT study for heart failure with preserved ejection fraction (HFpEF). This study aimed to determine if it improves outcomes in HFpEF patients, a condition lacking effective treatments.

Area of Science:

  • Cardiology
  • Pharmacology
  • Clinical Trials

Background:

  • Heart failure with preserved ejection fraction (HFpEF) is a complex condition with no proven therapies to improve patient outcomes.
  • Aldosterone antagonists have demonstrated survival benefits in patients with heart failure with reduced ejection fraction (HFrEF).
  • Preliminary studies suggested a potential benefit of aldosterone antagonists in HFpEF patients.

Purpose of the Study:

  • To evaluate the efficacy of spironolactone, an aldosterone antagonist, in improving clinical outcomes for patients diagnosed with HFpEF.
  • To investigate the role of spironolactone in managing HFpEF, a challenging heart failure subtype.

Main Methods:

  • The study, known as TOPCAT (Treatment of Preserved Cardiac Ejection Fraction Heart Failure with Aldosterone Antagonists), enrolled patients with HFpEF.
  • Spironolactone was administered to assess its effect on key clinical endpoints in this patient population.

Main Results:

  • The TOPCAT study investigated the impact of spironolactone on clinical outcomes in patients with HFpEF.
  • Results from the TOPCAT study are crucial for understanding spironolactone's potential role in HFpEF management.

Conclusions:

  • The TOPCAT study provides essential data on the effectiveness of spironolactone for heart failure with preserved ejection fraction.
  • Further analysis of TOPCAT findings will clarify the therapeutic value of aldosterone antagonists in HFpEF.

More Related Videos

Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine10:05

Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine

Published on: July 7, 2016

7.9K
Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing12:45

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing

Published on: December 11, 2017

10.2K

Related Concept Videos

Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
626
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
1.9K
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
632
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
1.6K
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
2.7K
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
689